Non-exclusive license providing Solid’s proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a ...

AAV-SLB101 is a rationally designed capsid developed for enhanced skeletal muscle, cardiac tropism, and reduced biodistribution to the liver.

Earlier this month, Gilead Sciences announced the first shipments of its twice-yearly injectable HIV-1 capsid inhibitor, ...

Explore how next-generation analytical methods empower researchers with accurate, consistent AAV titer measurement for gene ...

Investing.com -- Solid Biosciences Inc. (NASDAQ:SLDB) stock rose 6.1% on Monday after the company announced a non-exclusive worldwide license agreement with Andelyn Biosciences for its proprietary ...

Non-exclusive license providing Solid's proprietary, next-generation capsid, AAV-SLB101, to Andelyn Biosciences, a full-service cell and gene therapy Contract Development and Manufacturing Organizatio ...

Andelyn Biosciences has entered a non-exclusive worldwide license and collaboration agreement with Solid Biosciences Inc. for ...

A trial of lenacapavir showed 100% protection against HIV infection. But cuts to foreign aid and criticism over its pricing put the brakes on a worldwide rollout. Elna Schütz asks if we’re now seeing ...

Gilead Sciences shows strong growth potential with raised guidance, patent protection, and undervaluation. Learn more about ...

Cryo-EM revealed HIV-1 integrase’s distinct structures as it shifts between its two roles of DNA integration and RNA-binding.

Jefferies London Healthcare Conference 2025 November 17, 2025 10:00 AM ESTCompany ParticipantsLawrence Blatt - ...

Viruses in water pose major public health threats, yet their structural diversity makes them unequally susceptibility to ...